Mode
Text Size
Log in / Sign up

Pilot RCT finds oxygen therapy trial feasible for children with pneumonia and hypoxaemia in Malawi

Pilot RCT finds oxygen therapy trial feasible for children with pneumonia and hypoxaemia in Malawi
Photo by National Cancer Institute / Unsplash
Key Takeaway
Consider this a feasibility study; it does not establish efficacy for oxygen therapy in pediatric pneumonia.

This pilot randomized controlled trial assessed the feasibility of conducting a three-armed trial comparing standard care (no oxygen), low-flow nasal cannula (LFNC), and high-flow nasal cannula (HFNC) oxygen therapy. The study enrolled 21 children aged 1-59 months with WHO-defined pneumonia and an SpO2 of 90-93% at a district hospital in Malawi. The primary outcome was feasibility, defined as an average of ≤2 protocol deviations per participant.

The trial was found to be feasible, with an average of 0.8 protocol deviations per participant (16 deviations across 21 participants). A secondary outcome, treatment failure within 14 days, occurred in 3 of 21 participants (14.3%). No participants withdrew from the study. Safety data, including adverse events and tolerability, were not reported.

Key limitations include the pilot nature of the study and its small sample size (n=21). Funding sources and conflicts of interest were not reported. The study was designed to assess trial feasibility, not the efficacy or causality of oxygen therapy. Therefore, the results should not be interpreted as evidence for or against the use of LFNC or HFNC in this population. The findings support the feasibility of conducting a larger, definitive trial in this specific Malawian hospital setting.

Study Details

Study typeRct
Sample sizen = 21
EvidenceLevel 2
Follow-up59.0 mo
PublishedApr 2026
View Original Abstract ↓
OBJECTIVE: Oxygen is a cornerstone treatment for pneumonia with hypoxaemia. WHO guidelines recommend oxygen therapy for children with a peripheral arterial haemoglobin oxygen saturation (SpO) <90%. Children in low- and middle-income countries with an SpO of 90-93% are at increased risk of mortality and may benefit from oxygen therapy. We aimed to determine the feasibility of a randomised controlled trial comparing standard of care (no oxygen), low-flow nasal cannula (LFNC) and high-flow nasal cannula (HFNC) among children with pneumonia and an SpO of 90-93%. DESIGN: Pilot, open-label, three-armed randomised control trial (NCT06176664). SETTING: Salima District Hospital, Malawi. PATIENTS: Children 1-59 months old with WHO-defined pneumonia and an SpO of 90-93%. INTERVENTIONS: Standard care (no oxygen), LFNC or HFNC. MAIN OUTCOME MEASURES: The primary outcome was feasibility defined as an average of ≤2 protocol deviations per participant. Secondary outcomes included consent refusal, participant attrition and treatment failure within 14 days. Treatment failure was defined as an SpO <90% for standard care participants or <94% in the LFNC and HFNC arms despite maximum therapy as described, any new severe respiratory distress (grunting, very severe chest indrawing) or any new WHO-defined emergency sign. RESULTS: Of the 29 eligible patients, 21 (72%) were enrolled and randomised. There was an average of 0.8 (16/21) deviations per participant. Seven (43.8%) protocol violations were related to study intervention protocols and nine (56.3%) to medication availability and routine care. No participants withdrew from the study. Three of 21 participants (14.3%) had treatment failure. All participants were successfully followed to obtain the 14-day outcome. CONCLUSIONS: A three-armed, open-label randomised control trial is feasible to compare standard of care, LFNC and HFNC oxygen for children with pneumonia and an SpO of 90-93% in Malawi. TRIAL REGISTRATION NUMBER: NCT06176664.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.